Effects on gene expression of doxorubicin treatment in genome-edited human induced pluripotent stem cell-derived cardiomyocytes

To gain further insight into the mechanisms of doxorubicin-induced cardiotoxicty in genome-edited isogenic induced pluripotent stem cell-derived cardiomyocytes with or without the RARG variant S427L, we performed RNA-seq in doxorubicin- or vehicle-treated cardiomyocytes in both genotypes and investigate the differential expression genes as well as enriched molecular pathways. Overall design: hiPSC-derived cardiomyocytes of original (RARG-WT/S427L) and repaired (RARG-WT/WT) cell lines were treated with 1uM doxorubicin in experiment group and vehicle (DMSO) in control group in 12-well plates for 24 hours with 3 replicates in each condition.